2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Inflammation D007249 119 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Colitis D003092 69 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Starvation D013217 47 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Nervous System Diseases D009422 37 associated lipids
Epilepsy D004827 35 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Memory Disorders D008569 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Catalepsy D002375 30 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Obesity D009765 29 associated lipids
Neuralgia D009437 28 associated lipids
Hyperinsulinism D006946 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Brain Edema D001929 20 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Hypothermia D007035 19 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Encephalitis D004660 15 associated lipids
Hyperkinesis D006948 11 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Morphine Dependence D009021 9 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Brain Concussion D001924 5 associated lipids
Acute Pain D059787 3 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Fanelli F et al. Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women. 2017 Mol Metab pmid:28462075
Knani I et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. 2016 Mol Metab pmid:27900261
Banni S and Di Marzo V Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. 2010 Mol Nutr Food Res pmid:20013888
Rajaraman G et al. G protein coupled receptor 18: A potential role for endocannabinoid signaling in metabolic dysfunction. 2016 Mol Nutr Food Res pmid:26337420
Guasti L et al. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. 2009 Mol Pain pmid:19570201
Higgins A et al. Differential modulation of nociceptive versus non-nociceptive synapses by endocannabinoids. 2013 Mol Pain pmid:23725095
González-Mariscal I et al. Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice. 2016 Mol. Cell. Endocrinol. pmid:26724516
Battista N et al. The role of endocannabinoids in gonadal function and fertility along the evolutionary axis. 2012 Mol. Cell. Endocrinol. pmid:22305972
Szekeres M et al. Endocannabinoid-mediated modulation of Gq/11 protein-coupled receptor signaling-induced vasoconstriction and hypertension. 2015 Mol. Cell. Endocrinol. pmid:25595485
Costa MA et al. 2-Arachidonoylglycerol impairs human cytotrophoblast cells syncytialization: influence of endocannabinoid signalling in placental development. 2015 Mol. Cell. Endocrinol. pmid:25199616
Oláh M et al. The role of endocannabinoids in the regulation of luteinizing hormone and prolactin release. Differences between the effects of AEA and 2AG. 2008 Mol. Cell. Endocrinol. pmid:18308464
Gyombolai P et al. Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. 2012 Mol. Cell. Endocrinol. pmid:22075205
Catanzaro G et al. Effect of capacitation on the endocannabinoid system of mouse sperm. 2011 Mol. Cell. Endocrinol. pmid:21723369
Xu C et al. Endocannabinoids exert CB receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein. 2017 Mol. Cell. Neurosci. pmid:28733129
Fezza F et al. Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. 2014 Mol. Cell. Neurosci. pmid:25064144
Krishnan G and Chatterjee N Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity. 2014 Mol. Cell. Neurosci. pmid:24418364
Maccarrone M et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. 2005 Mol. Hum. Reprod. pmid:15563449
Patsenker E et al. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. 2011 Mol. Med. pmid:21863215
van der Stelt M et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. 2002 Oct-Dec Mol. Neurobiol. pmid:12428763
Luchicchi A and Pistis M Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. 2012 Mol. Neurobiol. pmid:22801993
Rockwell CE et al. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. 2006 Mol. Pharmacol. pmid:16611855
Raman P et al. 15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma. 2011 Mol. Pharmacol. pmid:21511917
Yates ML and Barker EL Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. 2009 Mol. Pharmacol. pmid:19389920
Jung KM et al. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. 2007 Mol. Pharmacol. pmid:17584991
Jäntti MH et al. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling. 2013 Mol. Pharmacol. pmid:23233488
Dinh TP et al. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. 2004 Mol. Pharmacol. pmid:15272052
He F et al. Involvement of the 90-kDa heat shock protein (Hsp-90) in CB2 cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration signaling of a G protein-coupled receptor. 2007 Mol. Pharmacol. pmid:17698952
Jain T et al. Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons. 2013 Mol. Pharmacol. pmid:23748223
Lichtman AH et al. Endocannabinoid overload. 2010 Mol. Pharmacol. pmid:20952498
Gonsiorek W et al. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. 2000 Mol. Pharmacol. pmid:10779390
Carrier EJ et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. 2004 Mol. Pharmacol. pmid:15044630
Laitinen T et al. Mutation of Cys242 of human monoacylglycerol lipase disrupts balanced hydrolysis of 1- and 2-monoacylglycerols and selectively impairs inhibitor potency. 2014 Mol. Pharmacol. pmid:24368842
Jung KM et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. 2005 Mol. Pharmacol. pmid:16051747
Straiker A et al. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. 2009 Mol. Pharmacol. pmid:19767452
Ouyang Y et al. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. 1998 Mol. Pharmacol. pmid:9547358
Guo J and Ikeda SR Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. 2004 Mol. Pharmacol. pmid:14978245
Delgado-Peraza F et al. Mechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor. 2016 Mol. Pharmacol. pmid:27009233
Neumeister A et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. 2013 Mol. Psychiatry pmid:23670490
Muccioli GG et al. The endocannabinoid system links gut microbiota to adipogenesis. 2010 Mol. Syst. Biol. pmid:20664638
Fezza F et al. Endocannabinoids, related compounds and their metabolic routes. 2014 Molecules pmid:25347455
Szafran BN et al. Characterization of Endocannabinoid-Metabolizing Enzymes in Human Peripheral Blood Mononuclear Cells under Inflammatory Conditions. 2018 Molecules pmid:30513753
Flores-Otero J et al. Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. 2014 Nat Commun pmid:25081814
Bluett RJ et al. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. 2017 Nat Commun pmid:28348378
Tung LW et al. Orexins contribute to restraint stress-induced cocaine relapse by endocannabinoid-mediated disinhibition of dopaminergic neurons. 2016 Nat Commun pmid:27448020
Jung KM et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. 2012 Nat Commun pmid:23011134
Alpár A et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. 2014 Nat Commun pmid:25030704
Iannotti FA et al. Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. 2018 Nat Commun pmid:30262909
Duggan KC et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. 2011 Nat. Chem. Biol. pmid:22053353
Hsu KL et al. DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses. 2012 Nat. Chem. Biol. pmid:23103940
Nomura DK et al. Activation of the endocannabinoid system by organophosphorus nerve agents. 2008 Nat. Chem. Biol. pmid:18438404
Long JZ et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. 2009 Nat. Chem. Biol. pmid:19029917
Kim J and Alger BE Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. 2004 Nat. Neurosci. pmid:15184902
Lourenço J et al. Synaptic activation of kainate receptors gates presynaptic CB(1) signaling at GABAergic synapses. 2010 Nat. Neurosci. pmid:20081851
Puente N et al. Polymodal activation of the endocannabinoid system in the extended amygdala. 2011 Nat. Neurosci. pmid:22057189
Self DW Anandamide: a candidate neurotransmitter heads for the big leagues. 1999 Nat. Neurosci. pmid:10204533
Giuffrida A et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. 1999 Nat. Neurosci. pmid:10204543
Shonesy BC et al. CaMKII regulates diacylglycerol lipase-α and striatal endocannabinoid signaling. 2013 Nat. Neurosci. pmid:23502535
Kim J and Alger BE Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. 2010 Nat. Neurosci. pmid:20348918
Maccarrone M et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. 2008 Nat. Neurosci. pmid:18204441
Di Marzo V Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. 2011 Nat. Neurosci. pmid:21187849
Makara JK et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. 2005 Nat. Neurosci. pmid:16116451
Marrs WR et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. 2010 Nat. Neurosci. pmid:20657592
Hohmann AG et al. An endocannabinoid mechanism for stress-induced analgesia. 2005 Nature pmid:15973410
Di Marzo V et al. Trick or treat from food endocannabinoids? 1998 Nature pmid:9872309
Panikashvili D et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. 2001 Nature pmid:11586361
Di Marzo V et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. 2001 Nature pmid:11298451
Wilson RI and Nicoll RA Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. 2001 Nature pmid:11279497
Stella N et al. A second endogenous cannabinoid that modulates long-term potentiation. 1997 Nature pmid:9285589
Feliszek M et al. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184. 2016 Naunyn Schmiedebergs Arch. Pharmacol. pmid:26984820
Schulte K et al. Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. 2012 Naunyn Schmiedebergs Arch. Pharmacol. pmid:22215206
Ameri A and Simmet T Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. 2000 Naunyn Schmiedebergs Arch. Pharmacol. pmid:10731038
Ilayan E et al. Do cannabinoids exhibit a tyramine-like effect? 2013 Naunyn Schmiedebergs Arch. Pharmacol. pmid:23900610
Jergas B et al. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24853577
Fernández-Suárez D et al. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. 2014 Neurobiol. Aging pmid:24973119
Arevalo-Martin A et al. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. 2010 Neurobiol. Dis. pmid:20156559
Piomelli D et al. Endogenous cannabinoid signaling. 1998 Neurobiol. Dis. pmid:9974178
Panikashvili D et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. 2006 Neurobiol. Dis. pmid:16364651
Vázquez C et al. Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. 2015 Neurobiol. Dis. pmid:25917763
Avraham Y et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. 2006 Neurobiol. Dis. pmid:16102970
Garcia-Ovejero D et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. 2009 Neurobiol. Dis. pmid:18930143
Melis M et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. 2006 Neurobiol. Dis. pmid:16762556
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
Duan Y et al. Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids. 2008 Neurochem. Int. pmid:17888543
Bardell TK and Barker EL Activation of TRPC6 channels promotes endocannabinoid biosynthesis in neuronal CAD cells. 2010 Neurochem. Int. pmid:20466028
Sang N et al. Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. 2010 Neurochem. Int. pmid:20064571
Best AR and Regehr WG Identification of the synthetic pathway producing the endocannabinoid that mediates the bulk of retrograde signaling in the brain. 2010 Neuron pmid:20159441
Oleson EB et al. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. 2012 Neuron pmid:22284189
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Gantz SC and Bean BP Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling. 2017 Neuron pmid:28262417
DeVuono MV et al. Conditioned gaping produced by high dose Δ-tetrahydracannabinol: Dysregulation of the hypothalamic endocannabinoid system. 2018 Neuropharmacology pmid:30195587
Shonesy BC et al. The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. 2015 Neuropharmacology pmid:25484252
Atwood BK et al. CBâ‚‚ cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. 2012 Neuropharmacology pmid:22579668
Walentiny DM et al. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. 2015 Neuropharmacology pmid:25698527
Kortleven C et al. Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. 2012 Neuropharmacology pmid:22884466
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
Pasquarelli N et al. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. 2015 Neuropharmacology pmid:25497453
Morena M et al. Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. 2016 Neuropharmacology pmid:27553121
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Wilkerson JL et al. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. 2017 Neuropharmacology pmid:27890602
Placzek EA et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 Neuropharmacology pmid:18760289